Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults - A Randomised Controlled Trial

NCT04608630 is registered in ClinicalTrials.gov with Australian and New Zealand Intensive Care Research Centre as lead sponsor.

NCT NCT04608630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04608630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults - A Randomised Controlled Trial
Lead sponsor
Australian and New Zealand Intensive Care Research Centre
Phase
Phase 2
Overall status
Recruiting
Start date
July 15, 2021
Completion date
February 28, 2027
Enrollment
450 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

critical illness, osteoporosis